Regulatory and ClinicalPositive Topline ResultsOct 5, 2026 · 5:23am ET
PCVXVaxcyte, Inc.
Vaxcyte Announced Positive Topline Data from OPUS-1 Phase 3 Trial of VAX-31
The pivotal adult Phase 3 trial results for the 31-valent pneumococcal conjugate vaccine candidate were positive.
Regulatory and ClinicalPositive Topline ResultsOct 5, 2026 · 5:23am ET
PCVXVaxcyte, Inc.+86.4%
Vaxcyte Announced Positive Topline Data from OPUS-1 Phase 3 Trial of VAX-31